|Application / Reactivity||Non-Human Primate||Human|
|ELISA||1 Antibodies||124 Antibodies|
|Immunocytochemistry (ICC)||1 Antibodies||9 Antibodies|
|Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))||1 Antibodies||60 Antibodies|
|Western Blotting (WB)||1 Antibodies||211 Antibodies|
|Dot Blot (DB)||36 Antibodies|
|Enzyme Immunoassay (EIA)||7 Antibodies|
|Flow Cytometry (FACS)||20 Antibodies|
|Immunofluorescence (IF)||40 Antibodies|
|Immunofluorescence (Paraffin-embedded Sections) (IF (p))||46 Antibodies|
|Immunohistochemistry (IHC)||97 Antibodies|
|Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections) (IHC (fp))||1 Antibodies|
|Immunohistochemistry (Frozen Sections) (IHC (fro))||12 Antibodies|
|Immunoprecipitation (IP)||40 Antibodies|
|Proximity Ligation Assay (PLA)||2 Antibodies|
|Antigen||Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A) Antibodies|
|Reactivity||Human, Non-Human Primate Alternatives|
|Conjugate||This CDKN1A antibody is un-conjugated Alternatives|
Immunocytochemistry (ICC), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), ELISA, Western Blotting (WB)
|5 references available|
|Supplier||Log in to see|
Product Details anti-CDKN1A AntibodyTarget Details CDKN1A Application Details Handling References for anti-CDKN1A Antibody (ABIN94444) Images
|Specificity||The antibody WA-1 reacts with p21 protein (Waf1, Cip1, SDI 1), a 21 kDa tumour suppressor, which inhibits the activity of cyclin-dependent family kinases and of proliferating cell nuclear antigen.|
|Purification||Purified from ascites by precipitation methods.|
|Purity||> 95 % (by SDS-PAGE)|
|Immunogen||Human p21 protein|
Target Details CDKN1AProduct Details anti-CDKN1A Antibody Application Details Handling References for anti-CDKN1A Antibody (ABIN94444) Images back to top
|Alternative Name||CDKN1A (CDKN1A Antibody Abstract)|
|Background||The tumour suppressor p21Waf1 (Wild-type p53-Activated Fragment 1, also known as Cip1, Cdk interacting protein, or SDI 1) is a cyclin-dependent kinase (Cdk) inhibitor, which is expressed by involvement of p53, Egr-1, AP2, STATs or other transcription factors upon various stimuli resulting in cell cycle arrest. Through its N-terminal domain p21Waf1 inhibits Cdk activity, whereas through the C-terminal domain it inhibits the activity of PCNA (proliferating cell nuclear antigen) to activate DNA replication. Cytosolic location of p21 counteracts its inhibitory activities.|
|Pathways||p53 Signaling, PI3K-Akt Signaling, Cell Division Cycle, AMPK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway|
Application DetailsProduct Details anti-CDKN1A Antibody Target Details CDKN1A Handling References for anti-CDKN1A Antibody (ABIN94444) Images back to top
Immunohistochemistry (paraffin sections)
Positive tissue: colon carcinoma
Working concentrations should be determined by the investigator.
|Restrictions||For Research Use only|
HandlingProduct Details anti-CDKN1A Antibody Target Details CDKN1A Application Details References for anti-CDKN1A Antibody (ABIN94444) Images back to top
|Buffer||Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4|
|Precaution of Use||WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.|
|Handling Advice||Do not freeze.|
|Storage Comment||Store at 2-8 °C. Do not use after expiration date stamped on vial label.|
References for anti-CDKN1A Antibody (ABIN94444)Product Details anti-CDKN1A Antibody Target Details CDKN1A Application Details Handling Images back to top
|Product cited in:||
Kolár, Murray, Scott et al.: "Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer." in: Molecular pathology : MP, Vol. 53, Issue 1, pp. 15-8, 2000 (PubMed).
Choi, Kim, Bae et al.: "p21 Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression." in: Cancer research, Vol. 68, Issue 5, pp. 1369-77, 2008 (PubMed).
Keeshan, Cotter, McKenna: "Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway." in: British journal of haematology, Vol. 123, Issue 1, pp. 34-44, 2003 (PubMed).
Horký, Kuchtícková, Vojtesek et al.: "Induction of cell-cycle inhibitor p21 in rat ventricular myocytes during early postnatal transition from hyperplasia to hypertrophy." in: Physiological research / Academia Scientiarum Bohemoslovaca, Vol. 46, Issue 3, pp. 233-5, 1998 (PubMed).
Waga, Hannon, Beach et al.: "The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA." in: Nature, Vol. 369, Issue 6481, pp. 574-8, 1994 (PubMed).
ImagesProduct Details anti-CDKN1A Antibody Target Details CDKN1A Application Details Handling References for anti-CDKN1A Antibody (ABIN94444) back to top